Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 6INDUSTRY 3NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 66Other hematologic neoplasm 33Genitourinary 11Plasma cell 7Sarcoma 4Tumor-Agnostic 1Thoracic 1Dermatologic 1Classical hematology 1CNS 1

Conditions

Thymoma 1

Interventions

Cisplatin 40Carboplatin 40Paclitaxel 34Radiotherapy 32Docetaxel 19Pemetrexed 17Gemcitabine 17Etoposide 17Bevacizumab 11Radiosurgery 9Magnetic Resonance Spectroscopy 9Ramucirumab 8durvalumab 7Taxes 7Cetuximab 7pembrolizumab 6Specimen Handling 6Erlotinib Hydrochloride 6Irinotecan 5Gene Expression Profiling 5Filgrastim 5cediranib 4Vinorelbine 4Polymerase Chain Reaction 4Neoadjuvant Therapy 4Fluorodeoxyglucose F18 4Chemotherapy, Adjuvant 4Amplified Fragment Length Polymorphism Analysis 4tremelimumab 3osimertinib 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NETWORK × Prednisone × Thoracic × Clear all
NCT00003283 2023-06-15

Octreotide With or Without Prednisone in Treating Patients With Metastatic or Recurrent Thymoma

Eastern Cooperative Oncology Group

Phase 2 Completed
38 enrolled
Thoracic

Thymoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡